LUCD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	235 209
Average Volume	170 654
Market Cap	32.33M
EPS	$-0.250 ( 2024-03-26 )
Next earnings date	( $-0.270 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.530
ATR14	$0.00200 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	White Debra	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sparks Ronald M	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Lapidus Stanley	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Cox James L	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sokolov Jacque J	Buy	150 000	Employee stock option (right to buy)

INSIDER POWER
33.50
Last 57 transactions
Buy: 13 183 319 \| Sell: 4 158 892

Volume Correlation

Long: -0.02 (neutral)

Short: 0.09 (neutral)

Signal:(80.549) Neutral

Lucid Diagnostics Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lucid Diagnostics Inc. Correlation - Currency/Commodity

-0.14
( neutral )

0.02
( neutral )

0.00
( neutral )

0.30
( neutral )

Lucid Diagnostics Inc. Financials

Annual	2023
Revenue:	$2.43M
Gross Profit:	$-6.05M (-249.18 %)
EPS:	$-1.260

Q4	2023
Revenue:	$1.04M
Gross Profit:	$-1.05M (-100.58 %)
EPS:	$-0.260

Q3	2023
Revenue:	$783 000
Gross Profit:	$-851 000 (-108.68 %)
EPS:	$-0.340

Q2	2023
Revenue:	$159 000
Gross Profit:	$-1.39M (-874.21 %)
EPS:	$-0.270

Financial Reports:

No articles found.

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.